临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
Charter Board Meetings and Reports,464–465 465
Conflict of Interest,464 464
DMC Recommendations,466–467 467
Role of the Board,463 463
Sponsor’s Decisions and Announcements,468 468
Unscheduled Meetings,466 466
Data manager functions,441–442 442
Dear Healthcare Professional letter acne medications,456–457 457
appetite suppressants,457 457
birth control pills,455–456 456
run-in period and baseline adverse event detection,52 52
serious adverse event,424 424
unexpected adverse drug reaction,425 425
Advisory Committee meetings,600 600
ALL see Acute lymphocytic leukemia Allin study,347 347
Allocation concealment blinding comparison,112–113 113
enrollment over time,122–123 123